凋亡促进分子TFAR19在成人慢性髓性白血病骨髓细胞的异常表达  

Abnormal expression of a novel apoptosis-promoting molecule TFAR19(PDCD5) in the bone marrow cells from adult chronic myeloid leukemia

作　　者：阮国瑞[1] 陈珊珊[1] 常艳[1] 付家瑜[1] 王卉[1] 秦亚溱[1] 李金兰[1] 刘艳荣[1] 

机构地区：[1]北京大学血液病研究所人民医院,北京100044

出　　处：《北京大学学报（医学版）》2002年第6期676-679,共4页Journal of Peking University:Health Sciences

基　　金：北京大学人类疾病基因研究中心"985工程"基金资助项目~~

摘　　要：目的 :研究成人慢性髓性白血病 (chronicmyeloidleukemia ,CML)骨髓细胞凋亡促进分子———TFAR19的表达 ,以探讨TFAR19在CML发病及疾病进展中的作用。方法 :利用 15种不同荧光标记的单克隆抗体标记骨髓细胞 ,通过流式细胞术检测未治CML慢性期病人、CML加速 /急变期病人、及正常人骨髓不同细胞群细胞内TFAR19的表达。结果 :2 0例未治CML慢性期及 13例加速 /急变期病人骨髓总的有核细胞内TFAR19平均荧光强度明显低于 10例正常人组骨髓总的有核细胞 ,分别为 5 793± 15 36 ,72 6 0± 781,P <0 .0 1及 4 2 93± 10 82 ,72 6 0± 781,P <0 .0 1,其中未治CML慢性期及加速 /急变期病人骨髓粒细胞内TFAR19平均荧光强度低于正常人组骨髓粒细胞 ,分别为 6 2 4 0± 1734,8317± 72 6 ,P <0 .0 1,及 5 75 9± 14 87,8317± 72 6 ,P <0 .0 1;未治CML慢性期及加速 /急变期病人骨髓淋巴细胞内TFAR19平均荧光强度低于正常人组骨髓淋巴细胞 ,分别为 12 92± 6 39,2 2 71± 82 0 ,P <0 .0 1,及 12 31± 2 81,2 2 71± 82 0 ,P <0 .0 1。CML加速 /急变期病人总的有核细胞与未治CML慢性期病人相比 ,TFAR19表达进一步降低 ,分别为 4 2 93± 10 82 ,5 793± 15 36 ,P <0 .0 1。结论 :未治CML慢性期病人、CML加速 /急变期病人?Objective: To estimate a novel apoptosis promoting molecule TFAR19 expression in the bone marrow cells from adult chronic myelogenous leukemia (CML) for its significance in the pathogenesis and disease progression of CML. Methods: Flow cytometry (FCM)assay was used for detection of TFAR19 expression in different groups of cells from normal and CML patient bone marrows by 15 monoclonal antibodies with different fluorescent markers. Results: The mean TFAR19 fluorescence intensity was significantly lower in marrow nucleated cells(MNC)from the marrow of 20 untreated CML CP(chronic phase, CP) and 13 CML AP/BP(accelerated or blastic phase, AP/BP)patients than that from the marrow of 10 normal subjects(5 793±1 536 vs 7 260±781, P <0.01; 4 293±1 082 vs 7 260±781, P <0.01, respectively).TFAR19 fluorescence intensity was lower in the marrow granu locytes from CML CP and CML AP/BP patients than that from the normal(6 240±1 734 vs 8 317±726, P <0.01; 5 759±1 487 vs 8 317±725, P <0.01, respectively). Furthermore, the TFAR19 in the marrow lymphocytes from CML CP and CML AP/BP patients it was also lower than that from the normal(1 292±639 vs 2 271±820, P <0.01; 1 231±281 vs 2 271±820, P <0.01, respectively). In addition,in the marrow nucleated cells from CML AP/BP patientsit was further lower than that from CML CP patients (4 293±1 082 vs 5 793±1 536, P <0.01). Conclusion: It can be concluded that TFAR19 expression in marrow nucleated cells was lower in untreated CML patients versus the normal. TFAR19 expression was lower in the marrow granulocytes and lymphocytes with untreated CML CP and CML AP/BP patients versus the normal. It suggests that the abnormality of TFAR19 expression may play an important role in the evolution of CML.

关 键 词：白血病 髓样 慢性 凋亡 TRAR19 PDCD5 骨髓细胞 

分 类 号：R733.72[医药卫生—肿瘤]